Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine

por Kosloski, Matthew P., Li, Hong, Wang, Stanley, Mensa, Federico, Kort, Jens, Liu, Wei
Publicado 2023

Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc A...

por Tran, Tram T., Mehta, Darshan, Mensa, Federico, Park, Caroline, Bao, Yanjun, Sanchez Gonzalez, Yuri
Publicado 2018

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

por Foster, Graham R., Asselah, Tarik, Kopecky-Bromberg, Sarah, Lei, Yang, Asatryan, Armen, Trinh, Roger, Zadeikis, Neddie, Mensa, Federico J.
Publicado 2019

1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analys...

por Rockstroh, Jurgen K, Bhagani, Sanjay R, Orkin, Chloe, Soto-Malave, Ruth, Lacombe, Karine, Zhang, Zhenzhen, Wang, Stanley, Mensa, Federico, Trinh, Roger
Publicado 2018

1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks

por Sarrazin, Christoph, Tran, Tram, Dylla, Douglas, Feld, Jordan J, Arora, Sanjeev, Victor, David, Hu, Yiran B, Wang, Stanley, Mensa, Federico, Wyles, David L
Publicado 2018

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis

por Back, David, Belperio, Pamela, Bondin, Mark, Negro, Francesco, Talal, Andrew H., Park, Caroline, Zhang, ZhenZhen, Pinsky, Brett, Crown, Eric, Mensa, Federico J., Marra, Fiona
Publicado 2019

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

por Berger, Kristi L., Sarrazin, Christoph, Nelson, David R., Scherer, Joseph, Sha, Nanshi, Marquis, Martin, Côté-Martin, Alexandra, Vinisko, Richard, Stern, Jerry O., Mensa, Federico J., Kukolj, George
Publicado 2016

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

por Krishnan, Preethi, Pilot-Matias, Tami, Schnell, Gretja, Tripathi, Rakesh, Ng, Teresa I., Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Xie, Wangang, Larsen, Lois, Mensa, Federico J., Collins, Christine
Publicado 2018

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection

por Naganuma, Atsushi, Chayama, Kazuaki, Notsumata, Kazuo, Gane, Edward, Foster, Graham R., Wyles, David, Kwo, Paul, Crown, Eric, Bhagat, Abhi, Mensa, Federico J., Otani, Tetsuya, Larsen, Lois, Burroughs, Margaret, Kumada, Hiromitsu
Publicado 2019

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials

por Brown, Ashley, Welzel, Tania M., Conway, Brian, Negro, Francesco, Bräu, Norbert, Grebely, Jason, Puoti, Massimo, Aghemo, Alessio, Kleine, Henning, Pugatch, David, Mensa, Federico J., Chen, Yaozhu J., Lei, Yang, Lawitz, Eric, Asselah, Tarik
Publicado 2019

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

por Sarrazin, Christoph, Castelli, Francesco, Andreone, Pietro, Buti, Maria, Colombo, Massimo, Pol, Stanislas, Calinas, Filipe, Puoti, Massimo, Olveira, Antonio, Shiffman, Mitchell, Stern, Jerry O, Kukolj, George, Roehrle, Michael, Aslanyan, Stella, Deng, Qiqi, Vinisko, Richard, Mensa, Federico J, Nelson, David R
Publicado 2016

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

por Ng, Teresa I., Pilot-Matias, Tami, Tripathi, Rakesh, Schnell, Gretja, Krishnan, Preethi, Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Lu, Liangjun, Asatryan, Armen, Campbell, Andrew, Yao, Betty, Lovell, Sandra, Mensa, Federico, Lawitz, Eric J., Kort, Jens, Collins, Christine
Publicado 2018

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

por Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.
Publicado 2017

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

por Wyles, David, Poordad, Fred, Wang, Stanley, Alric, Laurent, Felizarta, Franco, Kwo, Paul Y., Maliakkal, Benedict, Agarwal, Kosh, Hassanein, Tarek, Weilert, Frank, Lee, Samuel S., Kort, Jens, Lovell, Sandra S., Liu, Ran, Lin, Chih‐Wei, Pilot‐Matias, Tami, Krishnan, Preethi, Mensa, Federico J.
Publicado 2018

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

por Asselah, Tarik, Zeuzem, Stefan, Soriano, Vicente, Bronowicki, Jean-Pierre, Lohse, Ansgar W., Müllhaupt, Beat, Schuchmann, Marcus, Bourlière, Marc, Buti, Maria, Roberts, Stuart K., Gane, Edward J., Stern, Jerry O., Voss, Florian, Baum, Patrick, Gallivan, John-Paul, Böcher, Wulf O., Mensa, Federico J.
Publicado 2015

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies

por Yao, Betty B., Fredrick, Linda M., Schnell, Gretja, Kowdley, Kris V., Kwo, Paul Y., Poordad, Fred, Nguyen, Kinh, Lee, Samuel S., George, Christophe, Wong, Florence, Gane, Edward, Abergel, Armand, Spearman, Catherine W., Nguyen, Tuan, Hung Le, Manh, Pham, Thuy TT., Mensa, Federico, Asselah, Tarik
Publicado 2020

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

por Gane, Edward, Poordad, Fred, Zadeikis, Neddie, Valdes, Joaquin, Lin, Chih-Wei, Liu, Wei, Asatryan, Armen, Wang, Stanley, Stedman, Catherine, Greenbloom, Susan, Nguyen, Tuan, Elkhashab, Magdy, Wörns, Marcus-Alexander, Tran, Albert, Mulkay, Jean-Pierre, Setze, Carolyn, Yu, Yao, Pilot-Matias, Tami, Porcalla, Ariel, Mensa, Federico J
Publicado 2019

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

por Poordad, Fred, Pol, Stanislas, Asatryan, Armen, Buti, Maria, Shaw, David, Hézode, Christophe, Felizarta, Franco, Reindollar, Robert W., Gordon, Stuart C., Pianko, Stephen, Fried, Michael W., Bernstein, David E., Gallant, Joel, Lin, Chih‐Wei, Lei, Yang, Ng, Teresa I., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Kort, Jens, Mensa, Federico J.
Publicado 2018

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

por Flamm, Steven, Mutimer, David, Asatryan, Armen, Wang, Stanley, Rockstroh, Jürgen, Horsmans, Yves, Kwo, Paul Y., Weiland, Ola, Villa, Erica, Heo, Jeong, Gane, Edward, Ryder, Stephen D., Welzel, Tania M., Ruane, Peter J., Agarwal, Kosh, Ng, Teresa I., Xue, Zhenyi, Lovell, Sandra S., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Trinh, Roger, Mensa, Federico J., Wyles, David L.
Publicado 2018

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

por Winokur, Patricia, Gayed, Juleen, Fitz-Patrick, David, Thomas, Stephen J., Diya, Oyeniyi, Lockhart, Stephen, Xu, Xia, Zhang, Ying, Bangad, Vishva, Schwartz, Howard I., Denham, Douglas, Cardona, Jose F., Usdan, Lisa, Ginis, John, Mensa, Federico J., Zou, Jing, Xie, Xuping, Shi, Pei-Yong, Lu, Claire, Buitrago, Sandra, Scully, Ingrid L., Cooper, David, Koury, Kenneth, Jansen, Kathrin U., Türeci, Özlem, Şahin, Uğur, Swanson, Kena A., Gruber, William C., Kitchin, Nicholas
Publicado 2023